Related references
Note: Only part of the references are listed.A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam et al.
LEUKEMIA (2021)
Rethinking immune checkpoint blockade: 'Beyond the T cell'
Xiuting Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
Zachary Davis et al.
BLOOD ADVANCES (2021)
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments
Olivier Demaria et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Emily J. Pomeroy et al.
MOLECULAR THERAPY (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Sean J. Judge et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Huang Zhu et al.
CELL STEM CELL (2020)
Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager
Martin Felices et al.
CANCER IMMUNOLOGY RESEARCH (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
Daniel A. Vallera et al.
CANCERS (2020)
Deciphering the Immunological Phenomenon of Adaptive Natural Killer (NK) Cells and Cytomegalovirus (CMV)
Samantha Barnes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies
Uwe Reusch et al.
CANCER RESEARCH (2020)
Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota et al.
CANCER RESEARCH (2020)
PRELIMINARY RESULTS OF AN ONGOING PHASE I TRIAL OF FT500, A FIRST-IN-CLASS, OFF-THE-SHELF, INDUCED PLURIPOTENT STEM CELL (IPSC) DERIVED NATURAL KILLER (NK) CELL THERAPY IN ADVANCED SOLID TUMORS
David Hong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts
Erica D. Warlick et al.
BLOOD (2020)
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
Ying Cheng et al.
CANCER BIOLOGY & MEDICINE (2020)
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy
Frank Cichocki et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
Bing Zheng et al.
CLINICAL CANCER RESEARCH (2019)
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Simona Sivori et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy
Jianming Wu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon et al.
CLINICAL CANCER RESEARCH (2019)
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Magdalena Klanova et al.
CLINICAL CANCER RESEARCH (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Dean A. Lee
IMMUNOLOGICAL REVIEWS (2019)
NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing
Isabel Prager et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger et al.
MABS (2019)
Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Antonino Bruno et al.
FRONTIERS IN IMMUNOLOGY (2019)
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
Daniela Pende et al.
FRONTIERS IN IMMUNOLOGY (2019)
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
Aleksander Salomon-Perzynski et al.
ADVANCES IN MEDICAL SCIENCES (2019)
CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
Jennifer Watkins-Yoon et al.
BLOOD (2019)
Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside
Karrune V. Woan et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
Linde M. Morsink et al.
BLOOD REVIEWS (2019)
Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Michelle L. Saetersmoen et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression!
Francesca R. Mariotti et al.
ONCOIMMUNOLOGY (2019)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley et al.
BLOOD ADVANCES (2019)
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
Cristiana Lo Nigro et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
Miriam Van den Nest et al.
SYSTEMATIC REVIEWS (2019)
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices et al.
BLOOD ADVANCES (2019)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Role of Galectins in Tumors and in Clinical Immunotherapy
Feng-Cheng Chou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Peixin Dong et al.
FRONTIERS IN ONCOLOGY (2018)
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Giulia Fornasier et al.
ADVANCES IN THERAPY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells
Linda Quatrini et al.
NATURE IMMUNOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia
Ying-Ping Jiang et al.
BLOOD ADVANCES (2018)
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
Hyun Don Yun et al.
BLOOD ADVANCES (2018)
The role of CD133 in cancer: a concise review
Paige M. Glumac et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Marcia L. Moss et al.
MEDIATORS OF INFLAMMATION (2017)
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis et al.
SEMINARS IN IMMUNOLOGY (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Sourav Paul et al.
FRONTIERS IN IMMUNOLOGY (2017)
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Frank Cichocki et al.
CANCER RESEARCH (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+Colorectal Cancer Cells
J. U. Schmohl et al.
TARGETED ONCOLOGY (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten et al.
CLINICAL CANCER RESEARCH (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Dinutuximab: A Review in High-Risk Neuroblastoma
Sheridan M. Hoy
TARGETED ONCOLOGY (2016)
Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
Joerg U. Schmohl et al.
ONCOTARGET (2016)
A Modular Assembly Platform for Rapid Generation of DNA Constructs
Elliot H. Akama-Garren et al.
SCIENTIFIC REPORTS (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
Heinrich Schlums et al.
IMMUNITY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
Thomas A. Waldmann
CANCER IMMUNOLOGY RESEARCH (2015)
Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
Xiaoyue Chen et al.
Journal for ImmunoTherapy of Cancer (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
Haoyu Sun et al.
CYTOKINE (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Fusion protein linkers: Property, design and functionality
Xiaoying Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack
Jamie A. Lopez et al.
BLOOD (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15•IL-15Rα Cytokine Compared to IL-15 Monomer
Elena Chertova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency
Tianxiang Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Strategies for the Production of Recombinant Protein in Escherichia coli
Gopal Jee Gopal et al.
PROTEIN JOURNAL (2013)
Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
David A. Knorr et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
Bree Foley et al.
BLOOD (2012)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Lishomwa C. Ndhlovu et al.
BLOOD (2012)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors
Jing Ni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Interleukin-15 biology and its therapeutic implications in cancer
Jason C. Steel et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Use of NK cell activity in cure by transplant
Wing Leung
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Inflammatory Skin and Bowel Disease Linked to ADAM17 Deletion
Diana C. Blaydon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
Sandra Lopez-Verges et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Cyril Fauriat et al.
BLOOD (2010)
Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors
Yenan T. Bryceson et al.
BLOOD (2009)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The Many Roles of FAS Receptor Signaling in the Immune System
Andreas Strasser et al.
IMMUNITY (2009)
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
Xiaoyu Hu et al.
IMMUNITY (2009)
IL-12-Dependent Inducible Expression of the CD94/NKG2A Inhibitory Receptor Regulates CD94/NKG2C+ NK Cell Function
Andrea Saez-Borderias et al.
JOURNAL OF IMMUNOLOGY (2009)
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies
B. M. Triplett et al.
LEUKEMIA (2009)
Cytokine-induced memory-like natural killer cells
Megan A. Cooper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Negative signaling by inhibitory receptors: the NK cell paradigm
Eric O. Long
IMMUNOLOGICAL REVIEWS (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for Self-HLA-B and HLA-C ligands
Junli Yu et al.
JOURNAL OF IMMUNOLOGY (2007)
Human NK cell education by inhibitory receptors for MHC class I
Nicolas Anfossi et al.
IMMUNITY (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules
NC Fernandez et al.
BLOOD (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Natural killer cell signaling pathways
E Vivier et al.
SCIENCE (2004)
Optimization of codon pair use within the (GGGGS)(3) linker sequence results in enhanced protein expression
R Trinh et al.
MOLECULAR IMMUNOLOGY (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
